Enochian Biosciences Gene Cell Therapies Cancer 2023

Enochian Biosciences presents its enhanced gene and cell therapy pipeline designed to leverage immune response against cancer and infectious diseases. The Nasdaq-listed company, headquartered in Los Angeles, outlines its clinical development strategy and funding position with approximately $79.4M raised to date and a pending $100M S-3 shelf registration.